|Bid||1,470.00 x 175400|
|Ask||1,515.00 x 417900|
|Day's Range||1,475.80 - 1,497.20|
|52 Week Range||1,236.40 - 1,625.00|
|PE Ratio (TTM)||44.51|
|Earnings Date||Oct 31, 2018|
|Forward Dividend & Yield||0.76 (5.12%)|
|1y Target Est||1,646.82|
The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines Brussels threatens legal action against UK over customs ...
** Coca-Cola Co said it bought Australia-based Organic & Raw Trading Co, known for its Mojo brand of kombucha tea, extending its push into healthier drinks. ** Nestle, Unilever, and Coca-Cola are among bidders for GlaxoSmithKline's Indian Horlicks nutrition business, expected to fetch more than $4 billion, four people familiar with the matter said. ** U.S.-based recreational vehicle maker Thor Industries has agreed to buy German family-owned peer Erwin Hymer Group in a deal valuing the company at 2.1 billion euros ($2.45 billion)including debt, Thor said.
Nestle (NESN.S), Unilever (ULVR.L) (UNc.AS) and Coca-Cola (KO.N) are among bidders for GlaxoSmithKline's (GSK.L) Indian Horlicks nutrition business, expected to fetch more than $4 billion, four people familiar with the matter said.
LONDON (Reuters) - GlaxoSmithKline (GSK.L) has hired Chris Corsico from German drugmaker Boehringer Ingelheim to fill the new role of senior vice-president development as the company reshapes its research ...
Nestle (NESN.S), Unilever (ULVR.L) (UNc.AS) and Coca-Cola (KO.N) are among bidders for GlaxoSmithKline's (GSK.L) Indian Horlicks nutrition business, expected to fetch more than $4 billion (3.03 billion pounds), four people familiar with the matter said. It was not clear which other companies were bidding, although Reckitt Benckiser (RB.L), a company eager to build up its consumer health operation, did not make an offer, two sources said. GSK, Nestle, Reckitt and Unilever declined to comment.
In the second quarter, Merck’s (MRK) Zepatier and Isentress reported revenues of $113.0 million and $305.0 million, respectively, which represented an ~78.0% decline and 8.0% growth on a YoY (year-over-year) basis. In the first half, Zepatier and Isentress reported net revenues of $243.0 million and $586.0 million, respectively.
Glaxo (GSK) submits a regulatory application in the EU for a single-tablet, two-drug regimen of dolutegravir and lamivudine for the first-line treatment of HIV-1 infection.
As we discussed earlier, a few of the pharmaceutical stocks that have surpassed the returns of the S&P 500 Index YTD (year-to-date) include Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK). Let’s take a look at the details of their market caps.
PHILADELPHIA (AP) — A Chinese scientist has pleaded guilty to conspiring to steal biopharmaceutical trade secrets from GlaxoSmithKline in what prosecutors said was a scheme to set up companies in China to market them.
Label expansion of Merck's (MRK) Keytruda and FDA approval of AstraZeneca's (AZN) leukemia drug grab headlines this week
On August 15, Johnson & Johnson (JNJ) and ViiV Healthcare, the HIV business subsidiary of GlaxoSmithKline (GSK), announced positive top-line results of their Phase 3 ATLAS (Antiretroviral Therapy as Long-Acting Suppression) trial. The regimen consists of Johnson & Johnson’s rilpivirine and ViiV Healthcare’s cabotegravir, which is injected once per month. The study evaluated this 2DR therapy with the standard of care three-drug daily oral regimen.
Johnson & Johnson (JNJ) is one of the major healthcare companies in the world. It operates through its pharmaceuticals, medical devices, and consumer business segments. Although its pharmaceutical business generates most of its sales, medical devices and consumer business include a number of leading brands in their respective market spaces.
Gilead executives talk about the future after reporting positive late-stage results for the company's experimental rheumatoid arthritis drug.
The Coca-Cola Co. is moving forward with its interest in GlaxoSmithKline Plc’s Indian malted milk drink company Horlicks Ltd, according to the Sunday Telegraph.
GlaxoSmithKline (GSK.L) said on Friday that U.S. health authorities had asked for more information about its Nucala drug for use in combating chronic obstructive pulmonary disease (COPD). GSK said it had received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its application for mepolizumab - the generic name for Nucala - as an add-on treatment to inhaled corticosteroid-based maintenance treatment.
GlaxoSmithKline said on Friday that U.S. health authorities had asked for more information about its Nucala drug for use in combating chronic obstructive pulmonary disease (COPD). GSK said it had received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its application for mepolizumab - the generic name for Nucala - as an add-on treatment to inhaled corticosteroid-based maintenance treatment.
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Tesla Inc (NASDAQ: TSLA ) stock was trading lower ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Sept. 6) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR )(announced positive ...
Novartis (NVS) announced today, September 6, that it has agreed to sell select portions of its Sandoz US portfolio to Aurobindo Pharma USA for $0.9 billion in cash and $0.1 billion in potential earn-outs. The select portions include the Sandoz US dermatology business and the generic US oral solids business. The deal includes ~300 products and additional development programs that will be transferred from Sandoz’s US portfolio to Aurobindo.
ZURICH/BENGALURU (Reuters) - New Novartis (NOVN.S) Chief Executive Vas Narasimhan has further reshaped the Swiss drugmaker, announcing on Thursday he is selling U.S. dermatology and generic pill assets to India's Aurobindo Pharma Ltd (ARBN.NS) for up to $1 billion. The deal, which comes after price pressure hurt the U.S. pills business, includes some 300 products. Novartis said the transaction will result in a roughly $70 million impairment, to be confirmed when it releases third-quarter results in October.